---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-070382"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2026-06-22T12:10:21+00:00"
generated_at: "2026-06-22T12:15:27.603619+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Allarity announces Trial-in-Progress poster for Phase 2 stenoparib at ESMO Gynaecological Cancers Congress 2026

## Summary
- Poster outlines Phase 2 trial of stenoparib (dual PARP/WNT inhibitor) for platinum-resistant ovarian cancer.
- Presented by Principal Investigator Dr. Kathleen N. Moore, expert in advanced ovarian cancer.
- No new clinical data reported; Trial-in-Progress design describes study rationale and design only.
- Conference held June 17–19, 2026 in Copenhagen, Denmark; poster displayed June 18, 2026.

## SEC filing metadata
- accession: 0001213900-26-070382
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2026-06-22T12:10:21+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390026070382/0001213900-26-070382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390026070382/ea0295409-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-070382
- JSON: https://secwatch.observer/filing/0001213900-26-070382.json
- Plain text: https://secwatch.observer/filing/0001213900-26-070382.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.